Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.
Ganesh R, Pawlowski CF, O'Horo JC, Arndt LL, Arndt RF, Bell SJ, Bierle DM, Borgen MD, Hanson SN, Heyliger A, Larsen JJ, Lenehan PJ, Orenstein R, Puranik A, Speicher LL, Tulledge-Scheitel SM, Venkatakrishnan AJ, Wilker CG, Badley AD, Razonable RR.
Ganesh R, et al. Among authors: arndt ll, arndt rf.
J Clin Invest. 2021 Oct 1;131(19):e151697. doi: 10.1172/JCI151697.
J Clin Invest. 2021.
PMID: 34411003
Free PMC article.